Relmada Therapeutics skyrockets following REL-1017 HAP study results Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Relmada Therapeutics (RLMD) up 43% after announcing top-line results of the human abuse potential study with REL-1017, a novel NMDA receptor channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder
- Powerbridge (PBTS) up 8% after revealing that the company is currently building a blockchain enabled supply chain management SaaS platform
UP AFTER EARNINGS -
- Tesla (TSLA) up 1%
- Raytheon Technologies (RTX) up 1%
- General Electric (GE) up 3%
- Fiserv (FISV) up 1%
- Boston Scientific (BSX) up 1%
- Sirius XM (SIRI) up 3%
- Corning (GLW) up 1%
DOWN AFTER EARNINGS -
- UPS (UPS) down 2%
- Roku (ROK) down 1%
- Stanley Black & Decker (SWK) down 1%
LOWER -
- Flora Growth (FLGC) down 11% after announcing it has signed a non-binding Letter of Intent to form a joint venture with Canadian based Avaria, the manufacturer and owner of KaLaya
Symbols:
GE FISV BSX SIRI TSLA - $658.27 /
+14.91 (+2.32%)
UPS ROKU GLW FLGC RLMD SWK PBTS RTX Keywords: Fly Intel, Wall Street, Top Stories, Stocks